Post by Tony Held on Jun 21, 2018 13:08:41 GMT -6
Protocol Breakdown is back! This week's episode is all about DT's and alcohol withdrawal. This topic was by special request. If YOU have an idea for a show, send it to cbcemp.foamed@gmail.com
Sources for this podcast and all future episodes are now available at Mendeley. You do have to have an account to play, but you can get all the articles and research papers directly on your device! Join the group at: www.mendeley.com/community/cbcemp/
Catch the podcast notes here
Sources
Erdur, B., Degirmenci, E., Kortunay, S., Yuksel, A., Seyit, M., & Ergin, A. (2012). Effects of pretreatment with etomidate, ketamine, phenytoin, and phenytoin/midazolam on acute, lethal cocaine toxicity. Neurological Research. doi.org/10.1179/1743132812Y.0000000097
Wong, A., Benedict, N. J., Armahizer, M. J., & Kane-Gill, S. L. (2015). Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome. Annals of Pharmacotherapy, 49(1), 14–19. doi.org/10.1177/1060028014555859
Cook, C. C. H. (2000). Prevention and Treatment of Wernicke-Korsakoff Syndrome. Alcohol and Alcoholism, 35(Supplement_1), 19–20. doi.org/10.1093/alcalc/35.Supplement_1.19
Sullivan, E. V, & Fama, R. (2012). Wernicke’s encephalopathy and Korsakoff’s syndrome revisited. Neuropsychology Review, 22(2), 69–71. doi.org/10.1007/s11065-012-9205-2
Mythbusting the Banana Bag. (n.d.). Retrieved June 18, 2018, from www.aliem.com/2014/11/mythbusting-banana-bag/
Davies, M. (2003). The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry & Neuroscience : JPN, 28(4), 263–274. Retrieved from www.ncbi.nlm.nih.gov/pubmed/12921221
Management of moderate and severe alcohol withdrawal syndromes - UpToDate. (n.d.). Retrieved June 18, 2018, from www.uptodate.com/contents/management-of-moderate-and-severe-alcohol-withdrawal-syndromes
Kumar, S., Porcu, P., Werner, D. F., Matthews, D. B., Diaz-Granados, J. L., Helfand, R. S., & Morrow, A. L. (2009). The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology, 205(4), 529–564. doi.org/10.1007/s00213-009-1562-z
Sources for this podcast and all future episodes are now available at Mendeley. You do have to have an account to play, but you can get all the articles and research papers directly on your device! Join the group at: www.mendeley.com/community/cbcemp/
Catch the podcast notes here
Sources
Erdur, B., Degirmenci, E., Kortunay, S., Yuksel, A., Seyit, M., & Ergin, A. (2012). Effects of pretreatment with etomidate, ketamine, phenytoin, and phenytoin/midazolam on acute, lethal cocaine toxicity. Neurological Research. doi.org/10.1179/1743132812Y.0000000097
Wong, A., Benedict, N. J., Armahizer, M. J., & Kane-Gill, S. L. (2015). Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome. Annals of Pharmacotherapy, 49(1), 14–19. doi.org/10.1177/1060028014555859
Cook, C. C. H. (2000). Prevention and Treatment of Wernicke-Korsakoff Syndrome. Alcohol and Alcoholism, 35(Supplement_1), 19–20. doi.org/10.1093/alcalc/35.Supplement_1.19
Sullivan, E. V, & Fama, R. (2012). Wernicke’s encephalopathy and Korsakoff’s syndrome revisited. Neuropsychology Review, 22(2), 69–71. doi.org/10.1007/s11065-012-9205-2
Mythbusting the Banana Bag. (n.d.). Retrieved June 18, 2018, from www.aliem.com/2014/11/mythbusting-banana-bag/
Davies, M. (2003). The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. Journal of Psychiatry & Neuroscience : JPN, 28(4), 263–274. Retrieved from www.ncbi.nlm.nih.gov/pubmed/12921221
Management of moderate and severe alcohol withdrawal syndromes - UpToDate. (n.d.). Retrieved June 18, 2018, from www.uptodate.com/contents/management-of-moderate-and-severe-alcohol-withdrawal-syndromes
Kumar, S., Porcu, P., Werner, D. F., Matthews, D. B., Diaz-Granados, J. L., Helfand, R. S., & Morrow, A. L. (2009). The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology, 205(4), 529–564. doi.org/10.1007/s00213-009-1562-z